Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Change in Acquisitions & Divestments (2019 - 2025)

Historic Change in Acquisitions & Divestments for KalVista Pharmaceuticals (KALV) over the last 5 years, with Q2 2025 value amounting to $20.2 million.

  • KalVista Pharmaceuticals' Change in Acquisitions & Divestments rose 3056.2% to $20.2 million in Q2 2025 from the same period last year, while for Apr 2025 it was $122.8 million, marking a year-over-year increase of 1699.97%. This contributed to the annual value of $122.5 million for FY2025, which is 1673.96% up from last year.
  • As of Q2 2025, KalVista Pharmaceuticals' Change in Acquisitions & Divestments stood at $20.2 million, which was up 3056.2% from $48.9 million recorded in Q4 2024.
  • Over the past 5 years, KalVista Pharmaceuticals' Change in Acquisitions & Divestments peaked at $48.9 million during Q4 2024, and registered a low of $11.6 million during Q1 2024.
  • In the last 3 years, KalVista Pharmaceuticals' Change in Acquisitions & Divestments had a median value of $32.5 million in 2023 and averaged $30.3 million.
  • Examining YoY changes over the last 5 years, KalVista Pharmaceuticals' Change in Acquisitions & Divestments showed a top increase of 5024.44% in 2024 and a maximum decrease of 1576.7% in 2024.
  • KalVista Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $32.5 million in 2023, then skyrocketed by 50.24% to $48.9 million in 2024, then tumbled by 58.65% to $20.2 million in 2025.
  • Its last three reported values are $20.2 million in Q2 2025, $48.9 million for Q4 2024, and $38.2 million during Q3 2024.